Organon (OGN) said Tuesday that the US Food and Drug Administration has extended its review of the company's supplemental new drug application for VTAMA cream to treat atopic dermatitis in children at least two years old and adults.
The extended review postpones the target action date to March 12, 2025 from the original target action date of Dec. 12, according to the company.
With the new target action date, Organon said it expects about $125 million revenue contribution from VTAMA and an about 75 basis point headwind to adjusted EBITDA margin in 2025.
Organon said the FDA extended the review period after determining that a major amendment to the supplemental new drug application is required based on additional information submitted by the company.
The FDA did not raise any safety and efficacy concerns, Organon added.
Organon shares were 4.5% lower in recent trading.
Price: 16.16, Change: -0.76, Percent Change: -4.49
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。